

References

-Abate N, Chandalia M, Snell PG et al: Adipose tissue metabolites and insulin resistance in nondiabetic Asian men. *J Clin Endocrinol Metab.* 2004; 89: 2750 -2755.

-Abbasi F, Brown BW Jr, Lamendola C et al: Relationship between obesity, insulin resistance and coronary heart disease risk. *J Am Coll Cardiol* 2002;**40**:937-43.

-Alessi MC, Peiretti F, Morange P et al: Production of plasminogen activator inhibitor 1 by human adipose tissue, possible link between visceral fat accumulation and vascular disease. *Diabetes* 1997;46:860-867.

-Alexander CM, Landsman PB, Teutsch SM et al: Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes and prevalence of coronary heart disease among NHANES III participants age 50 years and older. *Diabetes.* 2003 : 52: 1210-1214.

-Apridonidze T, Essah PA, Iaorno MJ et al: Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. *J Clin Endocrinol Metab.* 2005; 90: 1929 -1935.

-Aronson D, Rayfield EJ: How hyperglycemia promotes atherosclerosis.? *Cardiovasc Diabetol* 2002;1:1

- Assmann G, Schulte H:** Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster Study. *Am J Cardiol* 1992;70(7):733-7.
- Austin MA :**Plasma triglyceride and coronary heart disease. *Arterioscler Thromb* 1991; 11 (1):2-14
- **Baik I, Ascherio A, Rimm EB et al :** Adiposity and mortality in men. *Am J Epidemiol* 2000;152:264–271.
- Barter PJ, Brewer HB , Chapman MJ et al:** Cholesterol ester transfer protein, a novel target for raising HDL and inhibiting atherosclerosis. *Arterioscler Thromb Vase Biol* 2003;23:160-167.
- Barter P, Nicholls S, Rye KA et al:** Metabolic abnormalities and high-density lipoproteins. *Endocrinol Metab Clin North Am* 2004;33:393-403.
- Barnett AH, Bain SC, Bouter P et al:** Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. *N Engl J Med.* 2004;351: 1952-1961.
- Bergman RN, Van Citters GW, Mittelman SD et al:** Central role OF the adipocyte in the metabolic syndrome. *J Investig Med.* 2001; 49: 119-126.

- Berneis KK, Krauss RM, Rizzo M et al:** Metabolic origins and clinical significance of LDL heterogeneity. *J Lipid Res.* 2002; 43:1363-1379.
- Bray GA .** Program abstracts, NAASO annual meeting, October 12-15, 1996. *Obesity Res* 1996;4(suppl 1):1-70.
- Braunwald E, Starling RD, Douglas P et al :** heart disease a text book of cardiovascular medicine by W.B.Saunders 6th edition .2001.
- **Braunwald E , Antman EM , Beasey TW et al:** American college of cardiology and American heart association Committee on management of patients with unstable angina *J.AM coll Cardiol* 2002 40:1366-1374.
- Browning JD, Szczepaniak LS, Dobbins R et al:** Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. *Hepatology.* 2004; 40: 1387-1395
- Brunzell JD :** Increased apo B in small dense LDL particles predicts premature coronary artery disease. *Arterioscler Thromb Vase Biol.* 2005; 25: 474-475.
- Burchfiel CM, Laws A, Benfante R et al.** Combined effects of HDL cholesterol, triglyceride and total cholesterol concentrations on 18-year risk of atherosclerotic disease. *Circulation* 1995;92(6): 1430-6
- Buset Ríos N, Rodríguez E, Sparragón F et al :** Cardio-metabolic properties of manidipine: beyond lowering arterial pressure? *Nefrologia.* 2009 Jun;29(3):203-207.

- Butler J, Rodondi N, Zhu Y et al:** Health ABC Study: Metabolic syndrome and the risk of cardiovascular disease in older adults. *J Am Coll Cardiol* 2006; 47: 1595-1602.
- Cachill K , Ussar M , Cao N et al :** Cannabinoid type 1 receptor antagonist for smoking cessation .2007, doi 1002- 1658 .
- Calle EE, Teras LR, Thun MJ et al.** cardiovascular mortality with increasing body weight in both men and women in all age groups *Circulation* 2005;100(5):475-82.
- Carr MC, Brunzell JD, Hull RL et al :** Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. *J Clin Endocrinol Metab.* 2004; 89: 2601-2607.
- Carr DB , Utzschneider KM , Hull RL et al:** Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. *Diabetes.* 2004; 53:2087-2094.
- Castelli WP, Campos H, Blijlevens E et al:** Epidemiology of triglycerides: a view from lingham. *Am J Cardiol* 1992;70(19):3H-9H
- Casey DE .** Metabolic issues and cardiovascular disease in patients with psychiatric disorders. *Am J Med.* 2005; 118(suppl 2):15S-22S.

-Chaour M , Theroux P, Gilfix BM et al. True fasting serum insulin level, insulin resistance syndrome and coronary artery disease. *Coronary Artery Dis.* 1997;8:683-8.

-Chandalia M, Cabo-Chan AV Jr, Devaraj S et al: Elevated - plasma high-sensitivity, C-reactive protein concentrations in Asian Indians living in the United States. *J Clin Endocrinol Metab* 2003;88:3773-3776.

-Charls , Davidson ,Braunwald text book of cardiology by Zipper , Braunwald eds , project manger Robin davis , USA , 2005 ,P 447

- Chen YX , Wang XQ , Fu Y et al : pivotal role of inflammation in vascular endothelial dysfunction of hyperlipidemic rabbit and effects by atorvastatin *Int J Cardiol.* 2009 Jun 30.

-Chobanian AV, Bakris GL, Black HR et al: The Seventh Report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC 7 report. *JAMA.* 2003;289:2560 -2572.

-Clay MA, Pyle DH , Rye KA et al. Time sequence of the inhibition of endothelial adhesion molecule expression by reconstituted high density lipoproteins. *Atherosclerosis* 2001;**157**:23-29.

-Clinical Guidelines on the Identification, Evaluation and Treatment of Overweight and Obesity in Adults the Evidence Report. National Institutes of Health. *Obes Res.* 1998;6(suppl 2):51S-209S.

-Cockerill GW, Saklatvala J, Ridley SH et al. High-density lipoproteins differentially modulate cytokine-induced expression of E-selectin and cyclooxygenase-2. *Arterioscler Thromb Vase Biol* 1999;**19**:910-917.

-Cockerill GW, Huehns TY, Weerasinghe A et al. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. *Circulation* 2001;**103**:108-112.

-Collins R, Peto R, MacMahon S et al: Blood pressure, stroke and coronary heart disease: Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. *Lancet* 335:827-838, 1990.

-Considine RV, Considine EL, Williams CJ et al. Evidence against either a premature stop codon or the absence of obese gene mRNA in human obesity. *J Clin Invest* 1995;**95**:2986-8.

-Coughlin SR, Mawdsley L, Mugarza JA et al: Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. *Eur Heart J.* 2004; **25**:735-741.

-Davies MJ, Thomas AC : Plaque fissuring the cause of acute myocardial infarction, sudden death and crescendo angina. *Br Heart J* 1985 Apr; **53**(4): 363-73.

- Davies MJ , Woolf N, Katz DR et al:** Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. *Circulation* 1996; 94(8): 2013-20.
- De Pergola G, Pannacchiulli N :** Coagulation and fibrinolysis abnormalities in obesity. *J Endocrinol Invest.* 2002; 25:899 -904
- Dekker MJ , Lee S , Hudson R et al.** An exercise intervention without weight loss decreases circulating interleukin-6 in lean and obese men with and without type 2 diabetes mellitus. *Metabolism* 2007;56: 332– 8.
- Diercks DB , Kirk JD , Roe MT et al :** the obesity paradox in non-ST-segment elevation acute coronary syndromes: results from the Can Rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the American College of Cardiology/American Heart Association Guidelines Quality Improvement Initiative 2006 Jul;152(1):140-8 .
- Eggesbo JB, Hjermann I, Hostmark AT et al.** Lipopolysaccharide-induced monocyte procoagulant activity, fibrinopeptide A and PAI-I levels in persons with high or low levels of HDL-lipoprotein. *Thromb Res* 1993;**70**:161-171.
- Eisenstein E, Hochman JS , Kristinsson A et al:** body mass index and intermediate-term clinical outcomes after acute Coronary syndrome .*Am J Med* 2005 Sep;118(9):981-90.

- **Eriksson J, Taimela S , Koivisto VA et al:** Exercise and the metabolic syndrome. *Diabetologia* 1997; 40: 125-35.

- Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults:** Executive summary on the third report on the The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA* 2001; 285: 2486-97.

- Fagan TC , Deedwania PC :** The cardiovascular dysmetabolic syndrome. *Am J Med* 1998; 105: 77S-82S.

- Fayad ZA, Fuster V, Aguinaldo JG et al:** Clinical imaging of the high-risk or vulnerable atherosclerotic plaque, *Circulation Research* 89 (2001), pp. 305-316.

- Ferrannini E, Haffner SM, Mitchell BD et al:** Hyperinsulinemia: the key feature of a cardiovascular and metabolic syndrome. *Diabetologia*. 1991; 34: 416-422.

- **Fiore E .** subcutaneous and visceral fat distribution according to sex , age and weight evaluated by computed tomography 1987: 65 suppl 6255-6605 .

- Foster GD, Wyatt HR, Hill JO et al:** A randomized trial of a low-carbohydrate diet for obesity. *N Engl J Med*. 2003; 348:2082-2090.

- Ford ES , Giles WH, Mokdad AH et al:** the metabolic syndrome and mortality from cardiovascular disease and all causes , findings from

national health and nutrition examination survey II mortality study .atherosclerosis 2004 ;173:309-314.

-Franklin BA, Kahn JK, Gordon NF et al: A cardioprotective polypill , independent and additive benefits of lifestyle modification. *Am J Cardiol.* 2004;94:162-166.

-Fruchart MC, Nierman E , Stroes SG et al : New risk factors for atherosclerosis and patient risk ssessment. *Circulation.* 2004; 109 suppl 15-9.

-Fuller JH, Shipley MJ, Rose G et al: Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall study. *Lancet* 1980; 28: 1373-6.

-Garg A, Bantle JP, Henry RR et al: Effects of varying carbohydrate content of diet in patients with non-insulin-dependent diabetes mellitus. *JAMA.* 1994; 271: 1421-1428.

-Garg A, Misra A, Bantle JP et al: Lipodystrophies: rare disorders causing metabolic syndrome. *Endocrinol Metab Clin North Am.* 2004;33:305-331.

-Genuth S, Alberti KG, Bennett P et al: Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. *Diabetes Care.* 2003;26:3160 -3167.

-
- **George Argyrous** . Statistics for Research: With a Guide to SPSS, Second Edition (2005), SAGE UK, London.
- Gordon T, Castelli WP , Hjortland MC et al.** High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. *Am J Med* 1977;62:707-714.
- Gordon DH, Probstfield JL, Rifkind BM et al:** High-density lipoprotein: the implications of recent studies. *N Engl J Med*. 1989; 321: 1311-1316.
- Gordon DJ, Probstfield JL, Garrison RJ et al.** High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. *Circulation*. 1989;79:8-15
- Groop L** : Genetics of the metabolic syndrome. *Br J Nutr* 2000; 83 Suppl. 1: S39-48.
- Groop L , Orho-Melander M , Tuomi T et al:** The dysmetabolic syndrome. *Intern Med* 2001; 250: 105-20.
- Grundy SM** : Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. *Circulation*. 2002; 106: 2526 -2529
- Grundy SM** : Obesity, metabolic syndrome and cardio-vascular disease. *J Clin Endocrinol Metab*. 2004; 89: 2595-2600.

-Grundy SM, Cleeman JI, Merz CN et al: National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. *Circulation*. 2004;10:227-239.

-Grundy SM, Brewer HB Jr, Cleeman JI et al: American Heart Association; National Heart, Lung and Blood Institute, Definition of metabolic syndrome: Report of the National Heart, Lung and Blood Institute/American Heart Association conference on scientific issues related to definition. *Circulation* 2004; 109:433-438.

-Grundy SM, Vega GL, Yuan Z et al: Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). *Am J Cardiol*. 2005;95: 462-68.

- Grundy SM, Vega GL, McGovern ME et al: Diabetes Multicenter Research Group. Efficacy, safety and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. *Arch Intern Med*. 2002; 162:1568 -1576.

-Gustat J, Srinivasan SR, Elkasabany A et al: Relation of self-rated measures of physical activity to multiple risk factors of insulin resistance syndrome in young adults: the Bogalusa Heart Study. *J Clin Epidemiol*. 2002; 55: 997-1006.

-Gyongyosi M , Yang P, Hassan A et al. Coronary risk factors influence plaque morphology in patients with unstable angina. *Coron Artery Dis* 1999;**10**:211-9.

-Haim M, Benderly M, Brunner D et al. Elevated serum triglyceride Levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) Registry. *Circulation* 1999;100(5):475-82.

-Han KH, Han KO, Green SR et al. Expression of the monocyte chemoattractant protein-1 receptor CCR2 is increased in hypercholesterolemia. Differential effects of plasma lipoproteins on monocyte function. *J Lipid Res* 1999;**40**:1053-1063.

-Hanley AJ, Festa A, D'Agostino RB et al: Metabolic and inflammation variable clusters and prediction of type 2 diabetes Diabetes. 2004Jul;53(7):1773-81.

-Hayashi T, Boyko EJ, Leonetti DL et al: Visceral adiposity and the risk of impaired glucose tolerance: a prospective study among Japanese Americans. *Diabetes Care*. 2003; 26: 650-655.

- Hikita N , Ura N , Nakata T et al : Involvement of glucose metabolism abnormalities and insulin resistance in atherosclerotic coronary artery disease, *j cardiol* 1998 NOV;32(5)291-300.

-Higgins M. Epidemiology and prevention of coronary heart disease in families. *American Journal of Medicine*, 2000 .108(5), 387-395.

-**Huber K** . Plasminogen Activator Inhibitor Type-1 : Role for Failure of Thrombolytic Therapy. PAI-1 Resistance as a Potential Benefit for New Fibrinolytic Agents,2001) J Thromb Thrombolysis. 2001 May;11(3):195-202.

-**Huber K , Christ G , Wojeta J et al** : plasminogen activator inhibitor-1 in cardiovascular disease , 2001 thromb Res , 103 (57-519) .

-**International Diabetes Federation** .Worldwide definition of the metabolic syndrome. Available at: http://www.idf.org/webdata/docs/IDF_metabolic_syndrome_definition.pdf. Accessed August 24,2005.

-**Isomaa B, Henricsson M, Almgren P et al**. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683-689.

-**Jackson CA, Yudkin JS, Forrest RD et al**: A comparison of the relationships of the glucose tolerance test and the glycated haemoglobin assay with diabetic vascular disease in the community: the Islington Diabetes Survey. Diabetes Res Clin Pract 1992;17(2):111-23

-**János A** : Evidence-based optimal treatment strategy of patients with angina pectoris, Orv Hetil. 2008 Feb 17;149(7):293-8.

- **Jean-Pierre Després JP, Echahidi N, Mohty D et al**: Director of Research in Cardiology at Hospital Laval Research Centre, Université Laval, Québec City, Québec, Canada, the International Chair on Cardio-metabolic Risk is involved in various local as well as international activities 2007.

-Jensen MD, Haymond MW, Rizza RA et al: Influence of body fat distribution on free fatty acid metabolism in obesity. *J Clin Invest.* 1989; 83: 1168-1173 .

-Jeppesen J, Hein HO, Suadicani P et al. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. *Circulation* 1998;97(11): 1029-36

-Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association. *Heart* 1998;80 Suppl 2:S1-29.

-Jones PH, Davidson MH, Vasudevan AR, et al: Safety of statins effects on muscle and the liver , *Cleve Clin J Med.* 2005 Nov;72(11):990-3, 996-1001.

-Jpatfjager A , van Hinsbergh VW, Kostense PJ et al. Increased levels of soluble vascular cell adhesion molecule 1 are associated with risk of cardiovascular mortality in type 2 diabetes: the Hoorn study. *Diabetes* 2000; **49**:485-91.

-Juhan-Vague I , Alessi MC , Mavri A et al: Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and cardio-vascular risk.*J Thromb Haemost.*2003;1:1575-1579.

-Kannel WB, Brand FN, Abbott RD et al . Lipids, diabetes and coronary heart disease: insights from the Framingham study. *Am Heart J* 1985;110(5): 1100-7

- Kannisto K, Pietilainen KH, Ehrenborg E et al:** Over expression of beta-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: studies in young adult monozygotic twins. *J Clin Endocrinol Metab.* 2004; 89: 4414-4421.
- Kato M, Dote K, Sasaki S et al.** Coronary plaque vulnerability in metabolic syndrome: Assessment of carotid artery morphology in acute coronary syndrome. *Circ J* 2007; 71: 1229-1233.
- Kato M , Yokohama H , Dote K et al :** Impact of metabolic syndrome on coronary plaque vulnerability in Japanese women with acute coronary syndrome. 2008 *circ j* Jun;72(6):940-5.
- Kelley DE, Thaete FL, Troost F et al:** Subdivisions of subcutaneous abdominal adipose tissue and insulin resistance. *Am J Physiol Endocrinol Metab.* 2000;278:E941-E948
- Kern PA, Di Gregorio GB, Lu T et al:** Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance and tumor necrosis factor-alpha expression. *Diabetes.* 2003;52:1779 -1785
- Kershaw EE , Flier JS .** Adipose tissue as endocrine organ , 2004; 89 : 2548-56.
- Kim AH , Kerchner GA , Chei DW et al :** Blocking endotoxemia chapter 1 in CNS neuro protection , editor springs new york 2002, page 3-36 .
- Kissebah AH, Videlund N, Murray R et al.** Relation of body fat

distribution to metabolic complications of obesity. *J Clin Endocrinol Metab* 1982;54:254–60.

-Klein S, Burke LE, Bray GA et al: Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. *Circulation*. 2004; 110:2952-2967.

-Knowler WC, Barrett-Connor E, Fowler SE et al: Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med*. 2002;346:393-403.

- Kolovou GD, Anagnostopoulou KK, Salpea KD et al . The prevalence of metabolic syndrome in various populations. *Am J Med Sci*. 2007;333:362-71.

-Kragelund C, Kober L, Faber J et al: Metabolic syndrome and mortality in stable coronary heart disease . *Int J Cardiol*. 2007 Jun 11 ,93: 109:433-438.

-Kris-Etherton PM, Harris WS, Appel LJ et al: American Heart Association. Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids and cardiovascular disease. *Circulation*. 2002; 106: 2747-2757.

- Krolewski AS, Warram JH, Valsania P et al.** Evolving natural history of coronary artery disease in diabetes mellitus. *Am J Med* 1991;90(2A):56S-61S
- Kuusisto J, Mykkanen L , Pyorala K et al:** NIDDM and it`s metabolic control predict coronary heart disease in elderly subjects. *Diabetes* 1994;43(8):960-7.
- Laakso M, Gylling H, Hallikainen M et al :** Gene variants, insulin resistance and dyslipidaemia. *Curr Opin Lipidol.* 2004;15:115-120.
- Lakka HM , Laaksonmen DE, Lakka TA et al .**The metabolic syndrome & cardiovascular disease mortality in middle aged men. *JAMA* 2002 ,288:2709-2716
- Lara castro C , Fu Y , Garvey WT et al :** adiponictin , the metabolic syndrome and their mechanisms mediated risk for metabolic and cardiovascular disease 2007 Jun: 18 (3) 263-70.
- Lee G H, Proenca R, Montez JM et al.** Abnormal splicing of the leptin receptor in diabetic mice. *Nature* 1996;379:632-5.
- Liao Y, Kwon S, Shaughnessy S, et al:** Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. *Diabetes Care.* 2004; 27:978 -983.
- Liese AD, Mayer-Davis EJ , Haffner SM et al:** Development of the multiple metabolic syndrome: an epidemiological perspective. *Epidemiol Rev* 1998; 20: 157-72 .

- Libby P, Ridker PM ,Maseri A et al:** inflammation and atherosclerosis
Circulation 2002; 105-135.
- Lonn EM, Gerstein HC, Sheridan P et al :** Effect of ramipril and of
rosiglitazone on carotid intima-media thickness in people with impaired
glucose tolerance or impaired fasting glucose: STARR (STudy of
Atherosclerosis with Ramipril and Rosiglitazone).J Am Coll Cardiol.
2009 Jun 2;53(22):2028-35.
- Lupattelli G, Marchesi S, Lombardini R et al.** Mechanisms of high-
density lipoprotein cholesterol effects on the endothelial function in
hyperlipemia. Metabolism 2003;52:1191-1195.
- Mackness B, Hine D, Liu Y et al :** Paraoxonase-1 inhibits oxidised
LDL-induced MCP-1 production by endothelial cells. Biochem Biophys
Res Commun 2004;318:680-683.
- Malik S, Wong ND, Franklin SS et al.** The CAD, CVD and total
mortality in relation with metabolic syndrome. Circulation. 2004 Sep
7;110(10):1245-50. Epub 2004 Aug 23.
- Manninen V, Tenkanen L, Koskinen P et al.** Joint effects of serum
triglyceride and LDL cholesterol and HDL cholesterol concentrations on
coronary heart disease risk in the Helsinki Heart Study: implications for
treatment. Circulation 1992;85(1):37-45.
- Manson JE, Willet WC, Stampfer MJ et al :** Body weight and
mortality among women. *NEngl JMed*.1995;333:677-685.

- Martin LJ, North KE, Dyer T et al:** Phenotypic, genetic and genome-wide structure in the metabolic syndrome. *BMC Genet.* 2003;4(suppl):S95.
- Marso SP, Giorgi LV, Johnson WL et al.** Diabetes mellitus is associated with a shift in the temporal risk profile of in hospital death after percutaneous coronary intervention: an analysis of 25,223 patients over 20 years. *Am Heart J* 2003;145:270-7 .
- McGill HC, Kushwaha RS, Barnwell GM, et al .** The Geographic Pathology of Atherosclerosis. Baltimore, Md: Williams and Wilkins; 1986.
- McGill HC , McMahan CA, Herderick EE et al.** Obesity and atherosclerosis in youth. *Circulation.* 2002; 105: 2712-2718.
- McKeigue PM, Ferrie JE, Pierpoint T et al.** Association of early-onset coronary heart disease in South Asian men with glucose intolerance and by hyperinsulinemia. *Circulation.* 1993; 87: 152-161
- Meigs JB, Singer DE, Nathan DM et al:** Epidemiology of the metabolic syndrome. *Am J Manag Care* 2002; 8 Suppl. 11: S283-92.
- Mendall MA, Strachan DP, Butland BK et al :** C-reactive protein and it`s relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. *Eur Heart J* 2000;**21**:1584-90.

-Menzaghi C, Ercolino T, Paola RD et al : A haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome. 2002 Diabetes 51:2306–2312

-Mitchell GF, Moye LA, Braunwald E et al: Sphygmomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function. SAVE investigators. Survival and Ventricular Enlargement. Circulation 96:4254-4260, 1997.

-Mitch WE, Tang S, Atkins RC et al: Beneficial responses to modified diets in treating patients with chronic kidney disease. *Kidney Int Suppl.* 2005;94:S 133— S135.

-Montenegro MR, Solberg LA , Correa P et al : Obesity, body weight, body length and atherosclerosis. *Lab Invest.* 1968; 18: 134-143.

-Moreno PR , Murcia AM , Palacios IF et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 2000;**102**:2180-4.

- Moriwaka F , Shima K , Aravanis C et al. The seven countries study: 2289 deaths in 15 years. *Prev Med.* 1984; 13: 141-154.

-Moudry R, Spycher MO, Doran JE et al: Reconstituted high density lipoprotein modulates adherence of polymorphonuclear leukocytes to human endothelial cells. Shock 1997;7:175-181.

- Muller-Wieland D, Kotzka J, Knebel B et al** : Metabolic syndrome , hypertension and pathophysiology of insulin resistance. *Basic Res Cardiol.* 1998;93:131-134.
- **Murakami T, Ohsato K , Shima Ket al**: The relation between endothelial -dysfunction of coronary artery and major adverse coronary events. *J Am Coll Cardiol.* 2000;35(Suppl A):354A
- National Cholesterol Education Program (NCEP).** Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation.* 2002; 106: 3143-3421.
- Navab M, Imes SS, Hama SY et al.** Monocyte transmigration induced by modification of low density lipoprotein in cultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. *J Clin Invest* 1991;88:2039-2046.
- Neaton JD, Wentworth D, Lee DJ et al**: Serum cholesterol, blood pressure, cigarette smoking and death from coronary heart disease: Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. *Arch Intern Med.* 1992;152:56-64.
- Nesto R**: C-reactive protein and it`s role in inflammation:Type 2 diabetes, cardiovascular disease and the effects of insulin-sensitizing treatment with thiazolidinediones. *Diabet Med.*2004;21:810-817.

-Nicklas BJ , Rayan AS , Stamler J et al : visceral adipose tissue cut off associated with metabolic risk factors for coronary heart disease in women , 2003; 26:1413-20 .

-Nielsen S, Guo Z, Johnson CM et al: Splanchnic lipolysis in human obesity. *JClin Invest.* 2004; 113: 1582-1588.

-Nigam A, Murphy Pg, Allison TG, et al : Excess weight at time of presentation of myocardial infarction is associated with lower initial mortality risks but higher long term risks including recurrent re-infarction 2006 Jun J Cardiol 16;110(2):153-9.

-Nofer JR, Geigenmuller S, Gopfert C et al. High density lipoprotein-associated lysosphingolipids reduce E-selectin expression in human endothelial cells. *Biochem Biophys Res Commun* 2003;**310**:98-103.

-O'Donnell CJ, Ridker PM, Glynn RJ et al: Hypertension and borderline isolated systolic hypertension increase risks of cardio-vascular disease and mortality in male physicians. *Circulation* 95:1132-1137, 1997.

-Oram JF , Vaughan AM, Tang C et al: HDL apolipoproteins and ABCA1partners in the removal of excess cellular cholesterol. *Arterioscler Thromb Vase Biol* 2003;23:720-727.

-Park YW, Zhu S, Palaniappan L et al: metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. *Arch Intern Med.* 2003;163: 427-436.

-Pearson TA, Mensah GA, Alexander RW et al: Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. *Circulation*. 2003;107:499 -511.

-Pedersen TR, Olsson AG, Faergeman O et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). *Circulation* 1998;97(15): 1453-60.

- Pouliot MC, Despres JP, Lemieux S et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indices of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. *Am J Cardiol* 1994;73:460–8.

-Poulsen P, Levin K, Petersen I et al: Heritability of insulin secretion, peripheral and hepatic insulin action and intracellular glucose partitioning in young and old Danish twins. *Diabetes*. 2005; 54:275-283.

-Pretorius M, Rosenbaum DA, Lefebvre J et al . Smoking impairs bradykinin-stimulated t-PA release. *Hypertension*. 2002;39:767-771

-Razavian SM, Atger V, Giral P et al. Influence of HDL subfractions on erythrocyte aggregation in hypercholesterolemic men. *Arterioscler Thromb* 1994;**14**:361-366.

-Reaven GM , McLaughlin T, Hayden J et al: The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. *Endocrinol Metab Clin North Am.* 2004; 33:283-303.

-Reilly MP , Rader DJ, Tang D et al : The metabolic syndrome: more than the sum of it`s parts? *Circulation* 2003; 108: 1546-51

-Rmero COrral A ,Montori VM, Somers VK et al Association of body weight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies , **Lancet.**2006 Aug 19;368(9536):666-78.

-Rodicio JL, Tuomilehto J, Zanchetti A et al: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. *Lancet.* 1997;350(9080):757-64.

-Ross R, Fuster V, Glomset JA et al: The pathogenesis of atherosclerosis Philadelphia, Pa: Lippincott-Raven; 1996: 441-62.

-Ross R, Glomset JA , Shragge P et al :Atherosclerosis: an inflammatory disease. *N Engl J Med* 1999;**340**:115-26.

-Saely CH, Koch L, Schmid F et al. Adult Treatment Panel III 2001 but not International Diabetes Federation 2005 criteria of the metabolic syndrome predict clinical cardiovascular events in subjects who underwent coronary angiography. *Diabetes Care* 2006; 29: 901-917.

- Sattar N, Gaw A, Scherbakova O et al**: Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. *Circulation*. 2003; 108: 414-419.
- Schoenhagen P, Ziada KM, Kapadia SR et al**: Extent and direction of arterial remodeling in stable versus unstable coronary syndromes : an intravascular ultrasound study. *Circulation* 2000 Feb 15; 101(6): 598-603
- Scott CL** : Diagnosis, prevention and intervention for the metabolic syndrome. *Am J Cardiol* 2003; 92 (suppl):35i-42i.
- Scott M , James I , Stephan D et al** : Diagnosis and management of the metabolic syndrome .An American Heart Association /National heart ,Lung and Blood Institute Scientific Statement *Circulation* .2005; 12:2735-2752.
- **Sniderman AD** , Low-density lipoprotein lowering in type 2 diabetes mellitus . *Curr Opin Endocrinol Diabetes Obes*. 2007 Apr;14(2):116-23.
- Solymoss BC, Bourassa MG, Sinderman A et al**: Effect of increasing metabolic syndrome on coronary artery disease angiographic severity *Am J cardiol* 2004;93:159-164.
- Solymoss BC, Bourassa MG , Marcil M, et al**: Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity. *Am J Cardiol* 2004; 93:159-164.

-Sowers JR , Castro JP, Wui MA et al : Update on the cardio-metabolic syndrome. Clin Cornerstone 2002; 4: 17-22.

-Sprafka JM, Burke GL, Folsom AR et al. Trends in prevalence of diabetes mellitus in patients with myocardial infarction and effect of diabetes on survival: the Minnesota Heart Survey. Diabetes Care 1991;14(7):537-43

-Stary HC, Chandler AB, Dinsmore RE et al: A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1995 Sep 1; 92(5): 1355-74

-Stern L, Iqbal N, Seshadri P et al: The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: one-year follow-up of a randomized trial. *Ann Intern Med.* 2004;140:778 -785.

-Steinberg HO, Chaker H, Learning R et al. Obesity and insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. *J Clin Invest.* 1996;197:2601-2610

-Stephens TW, Basinski M, Bristow PK et al. The role of neuropeptide Y in the antiobesity action of the obese gene product. *Nature* 1995;377:530-2.

-Sundstrom J, Riserus U, Byberg L et al .The presence of the metabolic syndrome increases the risk of subsequent total and cardiovascular mortality BMJ. 2006 Apr 15;332(7546):878-82.

-The Lipid Research Clinics Coronary Primary Prevention Trial results. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64

-The Sixth Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 157:2413-2446, 1997.

-The European Group for the Study of Insulin Resistance (EGIR): Frequency of the WHO metabolic syndrome in European cohorts and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002; 28: 364-76.

-Thompson PD, Buchner D, Pina IL et al: American Heart Association Council on Nutrition, Physical Activity, and Metabolism Subcommittee on Physical Activity. Exercise and physical activity in the prevention and treatment' of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). *Circulation*. 2003; 107: 3109-3116.

-Timar O, Sestier F , Levy E et al: Metabolic syndrome X: a review. Can J Cardiol 2000; 16: 779-89.

-Trayhum P, Wood IS , Rigotti A ,et al: Adipokines: inflammation and the pleiotropic role of white adipose tissue. *BrJNutr*. 2004; 92: 347-355.

- Trigatti BL, Krieger M, Rigotti A et al.** Influence of the HDL receptor SR-BI on lipoprotein metabolism and atherosclerosis. *Arterioscler Thromb Vase Biol* 2003;23:1732-1738.
- Ukkola M ,Santovenni M , Wood IS et al :** adiponictin as a link between excess adiposity and associated co- morbidity 2003 , *mol med* 80 (11) 696-702 .
- Van Dielen FM, Buurman WA, Greve JW et al:** Macrophage inhibitory factor, plasminogen activator inhibitor-1and other acute phase proteins as inflammatory mediators normalize as a result of weight loss in morbidly obese subjects treated with gastric restrictive surgery. *J Clin Endocrinol Metab.* 2004;89:4062-4068.
- Von Eckardstein A, Hersberger M, Rohrer L et al:** Current understanding of the metabolism and biological actions of HDL. *Curr Opin Clin Nutr Metab Care.* 2005;8:147-152.
- Wadham C, Albanese N, Roberts J et al.** High-density lipoproteins neutralize C-reactive protein pro-inflammatory activity. *Circulation* 2004;**109**:2116-2122.
- Watson KE, Horowitz BN, Matson G et al :** Lipid abnormalities in insulin resistant states. *Rev Cardiovasc Med* 2003;4:228-236.
- Weisberg SP, McCann D, Desai M et al:** Obesity is associated with macrophage accumulation in adipose tissue. *J Clin Invest.* 2003;112:1796-1808.

-Werner C : Collateral function in chronic total coronary occlusion is related to duration of occlusion. *Circulation*,2001.

-Wilson PW, Rutter MK, Meigs JB et al: Estimating cardio-vascular disease risk and the metabolic syndrome: a Framingham view. *Endocrinol Metab Clin North Am*. 2004;33:467-481.

-Wilson PW, Abbott RD, Castelli WP et al . High density lipoprotein , cholesterol and mortality. The Framingham Heart Study. *Arteriosclerosis* 1988;8:737-741

-Wienbergen H ,Glitt AK, Heer T et al : The body mass index on occurrence and outcome of acute ST-elevation myocardial infarction. 2008 Feb;97(2):83-8. *Clin Res Cardiol*.

-World Health Organisation Consultation: Definition, diagnosis and classification of diabetes mellitus and it`s complications: report of the World Health Organisation Consultation. Geneva: World Health Organisation, 1999

-World Health Organisation (1998) Obesity: Preventing and managing the global epidemic. Report of the WHO consultation on obesity [WHO/NUT/NCD/981]. Geneva: WHO, 1997 Jun 3-5.

-Xia P, Vadas MA, Rye KA et al. High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against atherosclerosis by HDL. *J Biol Chem* 1999;274:33143-33147.

-Yudkin JS, Blauth C, Drury P et al: Prevention and management of cardiovascular disease in patients with diabetes mellitus: an evidence base. *Diabet Med* 1996; 13(9 Suppl 4): S101-21.

-Yudkin JS, Stehouwer CD, Emeis JJ et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance and endothelial dysfunction: a potential role for cytokines originating from adipose tissue *Arter Throm Vase Biol.* 1999;19:972-978

-Zeller M , Steg PG , Ravisy J et al : Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction .
Arch intern Med 2005, 165 :1192-8 .

-Zhang Y, Proenca R, Maffei M et al : Positional cloning of the mouse obese gene and it`s human homologue. *Nature* 1994;372:425-32.